Earnings Releases·Oct 30, 2026, 7:51 AM ET

AbbVie — Third Quarter 2026 Earnings Summary

Reported Q3 net revenues of $17.404 billion (up 10.3% reported, 10.5% operational) and adjusted diluted EPS of $3.82, representing a year-over-year increase of over 100%.
Raised full-year 2026 adjusted diluted EPS guidance range to $13.95–$13.99, excluding future acquired IPR&D and milestones expenses.
Immunology segment drove growth with Skyrizi and Rinvoq revenues up 22.7% and 23.9% respectively, while Humira declined 31.2%.
Completed the Apogee Therapeutics acquisition, increased the quarterly cash dividend by 5.2% to $1.82 per share, and established strategic AI partnerships with Valkai and Iambic.
Multiple pipeline assets advanced with FDA approvals for Juvmo and subcutaneous Skyrizi, alongside positive Phase 3 data for Lutikizumab, Qulipta, and Epkinly.